Menu Search
Equities

Reviva Pharmaceuticals Holdings, Inc.

RVPH:NAQ

Reviva Pharmaceuticals Holdings, Inc.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.25
  • Today's Change-0.06 / -4.58%
  • Shares traded104.80k
  • 1 Year change-75.05%
  • Beta-0.1024
Data delayed at least 15 minutes, as of Sep 20 2024 18:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Reviva Pharmaceuticals Holdings, Inc.'s net income fell 38.92% from a loss of 28.26m to a larger loss of 39.26m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-356.97%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, Reviva Pharmaceuticals Holdings, Inc. increased its cash reserves by 26.18%, or 4.85m. Cash Flow from Financing totalled 33.17m or -- of revenues. In addition the company used 28.32m for operations while cash used for investing totalled .
Cash flow per share-0.5494
Price/Cash flow per share--
Book value per share-0.2026
Tangible book value per share-0.2026
More ▼

Balance sheet in USDView more

Reviva Pharmaceuticals Holdings, Inc. has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 23.37m.
Current ratio0.5187
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -13.93%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		14.30
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.